However, Novo Nordisk, Ozempics manufacturer, released results from two clinical trials in November 2025 that showed that taking an oral GLP-1 didnt slow disease progression among people with Alzheimers compared to those who took a placebo
Waiting significantly longer means continuing to live with weight-related health impacts that could have been addressed
Reviewed feedback from Trustpilot, BBB, and Reddit
The National Institute for Health and Care Excellence, known as NICE, is still reviewing it to decide whether the NHS should fund it
Yes not because of the medication itself, but because undernutrition is a real and often overlooked risk factor
Sugerman HJ, DeMaria EJ, Felton WL III, Nakatsuka M, Sismanis A